2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications 2022, 13: 3140. PMID: 35668129, PMCID: PMC9170782, DOI: 10.1038/s41467-022-30615-x.Peer-Reviewed Original ResearchConceptsType 1 immunityInternal organ involvementOrgan involvementT cell-derived IFNIdiopathic inflammatory disorderOpen-label trialMonths of treatmentType 1 cytokinesJanus kinase inhibitorImmunologic changesLongstanding sarcoidosisSarcoidosis activitySarcoidosis symptomsClinical improvementCutaneous sarcoidosisSecondary outcomesComplete responsePrimary outcomeTofacitinib treatmentActivity scoreCytokine mediatorsIL-12IL-15IL-6Inflammatory disorders
2009
Healthcare for Obstructive Lung Disease in an Industrial Spirometry Surveillance Program
Gulati M, Slade MD, Fiellin MG, Cullen MR. Healthcare for Obstructive Lung Disease in an Industrial Spirometry Surveillance Program. Journal Of Occupational And Environmental Medicine 2009, 51: 336-342. PMID: 19225419, PMCID: PMC3711683, DOI: 10.1097/jom.0b013e3181954ae6.Peer-Reviewed Original ResearchConceptsAirflow obstructionObstructive lung diseaseLung diseaseSurveillance programUndiagnosed airflow obstructionHealth careAluminum production workersAluminum industry workersCross-sectional analysisRespiratory surveillanceMild obstructionLung functionPrimary outcomeBorderline obstructionPresence of claimsObstructionIndustry workersSectional analysisDiseaseFurther investigationCareInsurance claimsProduction workersWorkersSeverity